bimagrumab and tirzepatide Antibody blockade of activin type II receptors preserves skeletal muscle mass enhances fat loss during GLP-1 receptor agonism Phase 2 Study of Bimagrumab

Clinical trials show that approximately 25-30% of total weight lost during GLP-1 receptor agonist therapy comes from lean tissue, including muscle

NICE guidance on type 2 diabetes management emphasises the importance of individualised dietary advice as part of comprehensive care, and this becomes even more relevant when managing medication side effects that affect eating patterns and food choices

and our Online Prescription Service explain how proper online prescribing works in Australia

This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide)